Investigational NNC0165-1875 Explored Alone and With Semaglutide for Weight Management in Overweight/Obese Individuals

Obesity and overweight represent significant global health challenges, contributing to numerous comorbidities like type 2 diabetes, cardiovascular disease, and certain cancers. Current pharmacological interventions, while effective, often have limitations in terms of efficacy, tolerability, or patient response, necessitating the exploration of novel therapeutic strategies. Glucagon-like peptide-1 receptor (GLP-1R) agonists like semaglutide have demonstrated substantial weight loss benefits by enhancing satiety and reducing appetite. However, the potential for even greater efficacy through combination therapies targeting multiple pathways remains a key area of research, aiming to provide more robust and personalized treatment options for individuals struggling with weight management. This study investigates such a novel combination.

This two-part, randomized, placebo-controlled clinical study investigated the safety and pharmacokinetics of investigational compound NNC0165-1875 alone or in combination with semaglutide in people who are overweight or obese. Part 1 involved a single subcutaneous (SC) injection of NNC0165-1875 or placebo. Part 2 involved a single SC injection of NNC0165-1875 or placebo, alongside a single SC injection of semaglutide. Participants received injections from a study nurse in a skin fold on the stomach. The study duration was approximately 9 weeks, including 7 clinic visits. The primary endpoint was the change in body weight from baseline to study end, comparing the effects of the active treatments against placebo.